Dare Bioscience (NASDAQ:DARE) Trading Up 13.6%

Dare Bioscience Inc (NASDAQ:DARE)’s share price was up 13.6% on Monday . The stock traded as high as $0.83 and last traded at $0.82, approximately 146,372 shares changed hands during mid-day trading. A decline of 71% from the average daily volume of 504,754 shares. The stock had previously closed at $0.72.

Several equities analysts recently weighed in on DARE shares. Maxim Group started coverage on Dare Bioscience in a research note on Monday, September 9th. They issued a “buy” rating and a $3.00 price target for the company. Aegis started coverage on Dare Bioscience in a research note on Thursday, August 22nd. They issued a “buy” rating for the company. Finally, ValuEngine upgraded Dare Bioscience from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd.

The company has a 50 day moving average of $0.79 and a two-hundred day moving average of $0.90. The stock has a market cap of $12.84 million, a PE ratio of -0.75 and a beta of 1.91.

Dare Bioscience (NASDAQ:DARE) last announced its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.09). On average, analysts predict that Dare Bioscience Inc will post -0.88 EPS for the current fiscal year.

A hedge fund recently raised its stake in Dare Bioscience stock. Susquehanna International Group LLP lifted its holdings in Dare Bioscience Inc (NASDAQ:DARE) by 293.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,770 shares of the biotechnology company’s stock after purchasing an additional 31,900 shares during the period. Susquehanna International Group LLP owned about 0.26% of Dare Bioscience worth $36,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 5.11% of the company’s stock.

About Dare Bioscience (NASDAQ:DARE)

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

Featured Story: Stocks at 52 Week High

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.